Polish experience of XXXX in the treatment of lower risk @entity2590 with isolated del(5q).

@entity1 @entity137 @entity882 @entity2590 @entity3052 @entity1398 @entity6985
BACKGROUND: @entity6985 has been approved for the treatment of lower-risk @entity2590 ( @entity2590 ) with 5q deletion (del(5q)). We present for the first time a retrospective analysis of low-risk @entity2590 with isolated del5q treated with @entity6985 , outside the clinical trials. METHODS: 36 red blood cell (RBC) transfusion-dependent @entity1 have been included in the study. @entity1 received @entity6985 10  mg/day on days 1-21 of 28-day cycles. RESULTS: 91.7  % of @entity1 responded to @entity6985 treatment: 72.2  % achieved erythroid response, 19.4  % achieved minor erythroid response and 8.4  % of @entity1 did not respond to treatment. Response depended on number of previous treatment lines (p   =   0.0101), International Prognostic System Score (IPSS; p   =   0.0067) and RBC transfusion frequency (p   =   0.0139). Median duration of response was 16  months (range 6-60 months). Treatment was well tolerated. We observed hematological @entity137 (grade 3 and 4): @entity1398 in 16 (44.4  %) @entity1 and @entity882 in 9 (25  %) @entity1 . Two @entity1 (5.5  %) progressed to high-risk @entity2590 and two subsequent progressed to @entity3052 . A Kaplan-Meier estimate for overall survival at 5  years in the study group was 79.0        8.8  %. CONCLUSIONS: @entity6985 in this group of @entity1 was beneficial for the treatment of RBC transfusion-dependency with well-known safety profile.
